US 12,268,691 B2
Treating extrapyramidal syndrome using trapidil
Aarash Bordbar, San Diego, CA (US)
Assigned to SINOPIA BIOSCIENCES, INC., San Diego, CA (US)
Filed by Sinopia Biosciences, Inc., San Diego, CA (US)
Filed on Mar. 1, 2023, as Appl. No. 18/176,962.
Application 18/176,962 is a continuation of application No. 16/503,128, filed on Jul. 3, 2019, granted, now 11,628,170.
Application 16/503,128 is a continuation of application No. 15/962,999, filed on Apr. 25, 2018, granted, now 10,350,212, issued on Jul. 16, 2019.
Application 15/962,999 is a continuation of application No. PCT/US2017/025788, filed on Apr. 3, 2017.
Claims priority of provisional application 62/317,983, filed on Apr. 4, 2016.
Prior Publication US 2023/0201205 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 31/198 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 25/14 (2006.01); A61P 25/18 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/198 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 25/14 (2018.01); A61P 25/18 (2018.01)] 20 Claims
 
1. A method for treating or preventing levodopa-induced dyskinesia in a subject, the method comprising administering to the subject a Trapidil compound or a pharmaceutically acceptable salt thereof.